Anti-PD-1 (nivolumab and pembrolizumab) and anti-CTLA-4 (ipilimumab) mAbs are FDA approved for melanoma. Many others entering clinical trials for NSCLC, RCC and kidney cancers. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.